π¬ Current Disease Focus:
Task Progress: 0%
π₯ Active Problem Solvers
0
π Experts collaborating globally
β‘ Current Task Assignment
𧬠Genetic Analysis
π Matching experts to specific tasks
π Resource Allocation by Research Phase:
π Data Analysis
π§ͺ Experimental Design
π¬ Clinical Trials
π Treatment Development
Primary trial objective in this single arm trial is to assess the safety an...
Status
Completed
Location
Department of Thoracic Oncology, Netherlands Cancer Instiute - Antoni van Leeuwenhoek Hospital
Start Date
2009-04
Trial ID
NCT00879866
Treatments Being Tested
There will be 2 phases in this study. Patients will either be enrolled to t...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Start Date
2006-09
Trial ID
NCT00402116
Treatments Being Tested
This trial is divided into two parts, a dose-escalation study (phase 1) and...
Status
Suspended
Location
University of Alabama at Birmingham
Start Date
2013-08
Trial ID
NCT01933815
Treatments Being Tested
This randomized, double-blind, placebo-controlled, single ascending dose st...
Status
Completed
Location
Changi General Hospital; Clinical Trial & Research unit
Start Date
2013-12
Trial ID
NCT02015715
The purpose of this study is to evaluate the safety, tolerability, and prel...
Status
Active Not Recruiting
Location
University of Alabama At Birmingham
Start Date
2021-02-23
Trial ID
NCT04279847
Treatments Being Tested
The purpose of this study is to investigate the safety and activity in the ...
Status
Completed
Location
Arensia Clinical Research Unit
Start Date
2019-08-14
Trial ID
NCT04073498
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonis...
Status
Completed
Location
GSK Investigational Site
Start Date
2016-06-23
Trial ID
NCT02723955
RATIONALE: Placing a tumor antigen chimeric receptor that has been created ...
Status
Unknown
Location
Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital
Start Date
2015-10
Trial ID
NCT02580747
Treatments Being Tested
VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in p...
Status
Terminated
Location
Stanford University, School of Medicine, Stanford Cancer Institute
Start Date
2019-04-04
Trial ID
NCT03682055
Treatments Being Tested
This multicenter, open-label, Phase I study will evaluate the safety, effic...
Status
Completed
Location
University of Alabama at Birmingham
Start Date
2015-07-22
Trial ID
NCT02431208